We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current CCCC market cap is 240M. The company's latest EPS is USD -1.8770 and P/E is -1.85.
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 6.42M | 3.26M | 3.04M | 12.01M | 15.36M |
| Operating Income | -73.8M | -37.43M | -32.22M | -21.44M | -28.24M |
| Net Income | -70.7M | -34.75M | -28.36M | -17.72M | -24.67M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 21.38M | 33.2M | 45.79M | 31.1M | 20.76M |
| Operating Income | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M |
| Net Income | -42.57M | -66.34M | -83.89M | -128.18M | -132.49M |
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 375.01M | 376.45M | 398.37M | 381.09M | 376.06M |
| Total Liabilities | 141.3M | 130.34M | 140.09M | 134.04M | 133.4M |
| Total Equity | 233.71M | 246.11M | 258.28M | 247.06M | 242.66M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 118.26M | 400.14M | 506.77M | 430.84M | 376.45M |
| Total Liabilities | 119.23M | 119.35M | 117.16M | 141.61M | 130.34M |
| Total Equity | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M |
| Quarter End | Jun 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -52.12M | -106.84M | -18.12M | -23.09M | -47.23M |
| Investing | 68.68M | 158.35M | -53.4M | -65.1M | -64.94M |
| Financing | -1.43M | 45.49M | 34.58M | 34.72M | 45.22M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M |
| Investing | -1.62M | -190.51M | -189.34M | 58.42M | 158.35M |
| Financing | 244k | 348.93M | 171.4M | 1.15M | 45.49M |
| Market Cap | 240M |
| Price to Earnings Ratio | -1.85 |
| Price to Sales Ratio | 11.84 |
| Price to Cash Ratio | 1.94 |
| Price to Book Ratio | 1 |
| Dividend Yield | - |
| Shares Outstanding | 70.59M |
| Average Volume (1 week) | 1.76M |
| Average Volume (1 Month) | 1.93M |
| 52 Week Change | -50.76% |
| 52 Week High | 11.88 |
| 52 Week Low | 3.39 |
| Spread (Intraday) | 0.01 (0.29%) |
| Company Name | C4 Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.c4therapeutics.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
